Lymphocytic alveolitis: A surprising index of poor prognosis in patients with primary Sjogren's syndrome

Loading...
Thumbnail Image

Date

Authors

Dalavanga, Y. A.
Voulgari, P. V.
Georgiadis, A. N.
Leontaridi, C.
Katsenos, S.
Vassiliou, M.
Drosos, A. A.
Constantopoulos, S. H.

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Type of the conference item

Journal type

peer-reviewed

Educational material type

Conference Name

Journal name

Rheumatol Int

Book name

Book series

Book edition

Alternative title / Subtitle

Description

Twelve years ago we reported that lymphocytic alveolitis [or bronchoalveolar lavage (BAL) lymphocytosis] correlates with clinical pulmonary involvement in primary Sjogren's syndrome (pSS). Our thesis was based on subtle clinical and functional evidence of interstitial lung disease (ILD) in pSS patients with "high lymphocytic alveolitis" (>15% lymphocytes in BAL). This report is a follow-up study of these patients. Basic clinical and functional re-evaluation of the 22 patients with pSS, studied in 1991, emphasized the differences between those with alveolitis and those without alveolitis. There was no significant functional decline. There were, however, two statistically significant differences between the two groups: (1) only patients with BAL lymphocytosis had to be treated with steroids (5/12 vs. 0/10, P < 0.05) and (2) only patients with BAL lymphocytosis had died in the mean time (6/12 vs. 0/10, P < 0.01). The causes of death were various. On only two occasions were they related to respiratory infections while there were no deaths from respiratory failure secondary to ILD. BAL lymphocytosis appears to be a surprisingly serious index of dismal prognosis in patients with pSS. We offer no unifying pathophysiologic mechanism for it and, therefore, all we propose is that BAL is performed early, in as many patients with pSS as possible. These patients should then be followed up systematically, in order to evaluate if BAL lymphocytosis has any pathophysiologic importance in the development of clinically serious pSS, which is serious enough to lead to death.

Description

Keywords

Bronchoalveolar Lavage Fluid/cytology, Complement C3/analysis, Complement C4/analysis, Humans, Lung Diseases, Interstitial/etiology/mortality/*pathology, Middle Aged, Prognosis, Pulmonary Alveoli/*pathology, Pulmonary Fibrosis/diagnosis/etiology/pathology, Sjogren's Syndrome/*complications/mortality/*pathology/therapy

Subject classification

Citation

Link

http://www.ncbi.nlm.nih.gov/pubmed/16344933
http://www.springerlink.com/content/y7k12441n4147116/fulltext.pdf

Language

en

Publishing department/division

Advisor name

Examining committee

General Description / Additional Comments

Institution and School/Department of submitter

Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής

Table of contents

Sponsor

Bibliographic citation

Name(s) of contributor(s)

Number of Pages

Course details

Endorsement

Review

Supplemented By

Referenced By